In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones

Clinical and Experimental Rheumatology

Volumn 26, Issue 1, 2008, Pages 103-108

  Atzeni, Fabiola ^a,b   Sarzi Puttini, Piercarlo ^b   DePortu, Simona ^c   Cutolo, Maurizio ^d   Carrabba, Mario ^b   Straub, Rainer H ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

ACTH; Anti TNF agents; Cortisol; Hormonal axes; Psoriatic arthritis

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; CYCLOSPORIN A; ETANERCEPT; HYDROCORTISONE; HYDROXYPROGESTERONE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PSORIATIC ARTHRITIS; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT DURATION;

17-ALPHA-HYDROXYPROGESTERONE; ADRENOCORTICOTROPIC HORMONE; ADULT; ANDROSTENEDIONE; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 40749111478     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. MYERS WA, GOTTLIEB AB, MEASE P: Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006; 24: 438-47.
2. VEALE DJ, RITCHLIN C, FITZGERALD O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 64 (Suppl. 2): Ii26-9: ii26-ii29.
3. MEASE PJ: Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61: 298-304.
4. FURST DE, BREEDVELD FC, KALDEN JR et al.: Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNF-α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64 (Suppl. 4): Iv2-iv14.
5. KAVANAUGH A, TUTUNCU Z, CATALAN-SANCHEZ T: Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006; 18: 347-53.
6. WOOLACOTT NF, KHADJESARI ZC, BRUCE IN, RIEMSMA RP: Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review. Clin Exp Rheumatol 2006; 24: 587-93.
7. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385-90.
8. LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 20; 349: 2014-22.
9. STRAUB RH, HÄRLE P, SARZI-PUTTINI P, CUTOLO M: Tumor necrosis factor-neutralizing therapies improve altered hormone axes: An alternative mode of antiinflammatory action. Arthritis Rheum 2006; 54: 2039-46.
10. STRAUB RH, PONGRATZ G, SCHÖLMERICH J et al.: Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. Arthritis Rheum 2003; 48: 1504-12.
11. STRAUB RH, HÄRLE P, PONGRATZ G et al.: Low baseline serum cortisol predicts marked clinical improvement 7 days after initiation of anti-TNF antibody therapy in rheumatoid arthritis (Abstract). Arthritis Rheum 2006; 54: S411.
12. TAYLOR W, GLADMAN D, HELLIWELL P et al.: Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-73.
13. FRANSEN J, ANTONI C, MEASE PJ et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65: 1373-8.
14. GLADMAN DD, ANTONI C, MEASE P, CLEGG DO, NASH P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. 2): Ii14-7.
15. (GISONDI P, GIROLOMONI G, SAMPOGNA F, TABOLLI S, ABENI D: Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005; 15: 279-83.
16. ZACHARIAE H, ZACHARIAE R, BLOMQVIST K et al.: Quality of life and prevalence or arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108-13.
17. MEASE PJ, ANTONI CE, GLADMAN DD, TAYLOR WJ: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2): Ii49-ii54.
18. LEBWOHL M, TINGTPT, KOO JY: Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005; 64 (Suppl. 2): Ii83-6.
19. RITCHLIN C, HAAS-SMITH SA, HICKS D, CAPPUCCIO J, OSTERLAND CK, LOONEY RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.
20. JÄÄTTELÄ M, ILVESMAKI V, VOUTILAINEN R, STENMAN UH, SAKSELA E: Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991; 128: 623-9.